<DOC>
	<DOC>NCT02438644</DOC>
	<brief_summary>This observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (Erivedge) in Argentine patients. Only patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) will be considered in the effectiveness analysis. Study duration is estimated to be approximately 12 months.</brief_summary>
	<brief_title>Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<criteria>Argetine patients prescribed vismodegib according to standard of care and in line with Summary of Product Characteristics (SPC) and local labeling Diagnosis of laBCC or mBCC for the effectiveness analysis None specified</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>